Mechanistically, the p16 protein, as a negative regulator of the cell cycle, inhibits the activity of cyclin D1-dependent kinase 4 or 6 complex, which finally leads to G1/S transition arrest and tumour suppression. Here, CDKN2A is linked to neoplasm.